Ionis (IONS) Stock Looks Fully Valued As A Phase 3 Trial Miss Lands

Ionis Pharmaceuticals has seen its share price fall sharply this year, which puts a spotlight on whether the current market value lines up with the sales it is generating. After a fresh setback in a key partnered trial, investors are now weighing how the story for Ionis stock lines up against the revenue it produces today and what the market is willing to pay for that stream.

• The share price is down 41.3% year to date, which puts extra weight on the question of whether the revenue base can support the valuation that remains.
• Novartis recently reported that the pelacarsen Lp(a)HORIZON Phase 3 trial did not meet its primary endpoint, which can reshape expectations for how Ionis converts its pipeline into future product sales and partnership income.
• Your read on Ionis Pharmaceuticals is one view; the desks covering it have another. See what analysts think Ionis Pharmaceuticals's shares could be worth.

For investors, the debate is whether Ionis Pharmaceuticals' current market price is adequately supported by its sales given the recent setback and the stock's sharp year to date decline.

If you are weighing whether Ionis Pharmaceuticals' current price lines up with its sales, it can help to compare that question across 29 high quality undervalued stocks.

Does Ionis Pharmaceuticals Look Pricey on Sales?

The P/S multiple fits Ionis Pharmaceuticals because the business is still driven heavily by revenue and royalties rather than consistent earnings. On this yardstick, the stock trades on a P/S of 8.9x, which is below the biotech industry average of 12.4x and also below the peer group level of 16.3x. That means investors are currently paying less per dollar of sales for Ionis than for many comparable drug developers.

Based on a tailored fair P/S level that adjusts for factors such as growth profile, margins, risk and market size, Ionis Pharmaceuticals screens as overvalued because its current 8.9x sits above that figure. Because the pelacarsen Phase 3 miss has clouded part of the partnered pipeline, the present premium over this fair benchmark suggests buyers are still assigning meaningful value to the rest of Ionis' platform and collaborations despite that setback. Explore the numbers behind Ionis Pharmaceuticals's P/S valuation.

The Ionis Pharmaceuticals Narrative: What Would Justify Today's Price?

Ionis Pharmaceuticals' valuation puzzle sets up the role of Simply Wall St Narratives, which sit on the Community page and spell out what kind of future growth, profitability and earnings profile would need to unfold for the current share price to look meaningfully higher or lower. Each scenario links its number to a clear view on how revenue expansion, margins and key risks might evolve, giving you a reference point you can revisit as fresh results and trial updates emerge.

One of the top community narratives on Ionis Pharmaceuticals: 47% undervalued

"Expanding into larger patient populations and strong physician acceptance position Ionis for substantial market share gains and sustained top-line growth..."

Discover why this Narrative puts Ionis Pharmaceuticals at 47% undervalued.

The Ionis Pharmaceuticals story is bigger than today's share price

Analyst projections give you a separate lens on where Ionis Pharmaceuticals might be a few years from now, which you can weigh against the current multiples and pipeline setbacks. Explore where analysts expect Ionis Pharmaceuticals to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com